Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 4, Number 2—June 1998

Synopsis

Campylobacter jejuni Strains from Patients with Guillain-Barré Syndrome

Ban Mishu Allos*, Frank T. Lippy*, Andrea Carlsen*, Ronald G. Washburn†, and Martin J. Blaser*‡
Author affiliations: *Vanderbilt University School of Medicine,; ‡The Department of Veterans Affairs Medical Center, Nashville, Tennessee, USA; †The Bowman Gray School of Medicine, Winston-Salem, North Carolina, USA

Main Article

Table 2

Susceptibility of Campylobacter jejuni strains to killing by normal human serum (NHS)

Illness O serotype No. of strains studied No. (%) with
>1 log killa,
Median log kill (interquartile range)
Pool 1c Pool 2c Pool 1 Pool 2
GBSd 19 7 1 (14) 0 (0) 0.53 (0.18-0.63) 0.39 (0.08-0.52)
Enteritis 19 11 0 (0) 0 (0) 0.37 (0.09-0.47) 0.48 (0.29-0.50)
GBS non-19 10 3 (30) 3 (30) 0.70 (0.44-1.18) 0.43 (0.03-1.32)
Enteritis non-19 16 8 (50) 7 (44) 0.90 (0.24-2.00) 0.59 (0.35-2.53)
All 19 18 1 (6) 0 (0) 0.38 (0.17-0.58) 0.45 (0.23-0.52)
All non-19 26 11 (42) 10 (38) 0.70 (0.26-1.86) 0.54 (0.17-2.27)

aBacterial suspensions were incubated in either NHS or heat inactivated NHS at 37°C for 1 hr as described in text, and net CFU (NHS minus HINHS) determined. Values greater than 1 log10 kill were considered to denote a serum-susceptible strain.
bComparison of O:19 strains with non-O:19 strains: Pool 1, odds ratio = 12.5, p = 0.008; Pool 2, odds ratio = undefined, p = 0.003.
cPool 1 consists of C. jejuni-antibody positive serum from five healthy adults; Pool 2 consists of C. jejuni-antibody negative serum from two healthy adults.
dGBS = Guillain-Barré syndrome.

Main Article

TOP